When you have type 2 diabetes, your body isn’t able to properly use insulin to bring glucose into your cells.
A clinical research study is designed to answer questions about the safety and effectiveness of potential new procedures. These studies must be performed before a new procedure can be approved for use in patients.
The REVITA-T2Di Study will look at a potential procedure called duodenal mucosal resurfacing (DMR). The DMR procedure acts on the innermost layer (mucosa) of the duodenum (the part of the small intestine located immediately after the stomach). By removing an excess layer, the treatment may improve blood sugar control. This treatment may eliminate or reduce the need for insulin injections in the future.
Fractyl Health was founded in 2011 with a dedication to developing novel therapeutic interventions that have the potential to help reverse the metabolic disease epidemic. Despite advances in treatment over the past 50 years, metabolic diseases in general, and type 2 diabetes (T2D) in particular, continue to be a principal and rapidly growing driver of morbidity and mortality in the 21st century. Our goal is to transform T2D treatment from chronic blood glucose management to disease-modifying therapies that...